ClinicalTrials.gg
CompletedNCT03131583Updated Aug 8, 2019

The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout

A Phase 1 interventional study of Colchicine and Febuxostat in Gout, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-08-08.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing colchicine in Gout — 1 open to participants now, 1 under way, none of them phase 3. Colchicine · Gout.

Enrollment
9th of 10
15 · median 78
Started
2017
the only one that year
Phase 1
3 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
1 of 10
Jiangsu HengRui Medicine Co., Ltd.

Among the 10 studies testing colchicine in Gout, this one is the 9th largest by enrollment, is the only one that started in 2017, is one of 3 in phase 1, and was the 7th registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 10 studies testing colchicine in Gout is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About colchicine

Colchicine: first FDA approval 1961 (COLBENEMID), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing colchicine in Gout, or all of them as a file.
02

Study summary

The objective of the study is to assess the pharmacodynamic properties of drug-drug of SHR4640, Febuxostat and Colchicine interaction in patients with gout.

03

Conditions studied

  • Gout

Browse trials for

Keywords

  • SHR4640 Febuxostat Colchicine pharmacodynamics
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has a ≥18.5 and ≤30 kg/m2;
  2. Screening sUA value ≥8mg/dl;
  3. Subject has no abnormalities in vital signs, , physical examination,imaging examination or safety laboratory values.

Exclusion criteria

Exclusion Criteria:

  1. Subject known or suspected of being sensitive to the study drugs or its ingredient;
  2. sCr>;
  3. History of kidney stones or screening kidney stones by B-ultrasound;
  4. History of within 5 years;
  5. History of xanthinuria;
  6. Donated blood(≥400ml)within 3 months prior to screening or received transfusion of blood。
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Colchicine 0.5 mg Oral Tablet Day-14\~Day16 qd, Febuxostat 80 mg Oral Tablet Day1 and Day8 qd, SHR4640 10 mg Oral Tablet Day3\~Day8 qd.

    Drug: Colchicine · Drug: Febuxostat · Drug: SHR4640

Interventions

06

What researchers measure

Primary outcomes

  1. Maximun observed concentration (Cmax) of Febuxostat and Colchicine from plasma

    PK profile

    Time frame: Clinical significant changes from baseline up to Day 8

  2. Area under the concentration-time curve (AUC) of Febuxostat and Colchicine from plasma

    PK profile

    Time frame: Clinical significant changes from baseline up to Day 8

  3. Apparent terminal half-life (t1/2) of Febuxostat and Colchicine from plasma

    PK profile

    Time frame: Clinical significant changes from baseline up to Day 8

Secondary outcomes

  1. Incidence of Adverse events

    Safety issue

    Time frame: Clinical significant changes from Day-14 up to Day 16

  2. Changes in Laboratory Values

    Safety issue

    Time frame: Clinical significant changes from Day-14 up to Day 16

  3. Changes in Electrocardiogram

    Safety issue

    Time frame: Clinical significant changes from Day-14 up to Day 16

  4. Changes in Vital Signs Parameters

    Safety issue

    Time frame: Clinical significant changes from Day-14 up to Day 16

07

Study locations

1 site
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Jan 2018, 11 months.

Of 37 industry-sponsored phase 1 interventional studies under Gout, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 11 months is above that.

Counting every sponsor, half of 40 studies reached it within 6 months; a quarter within 1 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2017
First posted
Apr 27, 2017
StartActual
Feb 17, 2017
Primary completionActual
Jan 29, 2018
CompletionActual
Jan 29, 2018
Last update
Aug 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03131583
Responsible party
Sponsor
First posted
Apr 27, 2017
Start date
Feb 17, 2017
Primary completion
Jan 29, 2018
Completion
Jan 29, 2018
Last update
Aug 8, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Colchicine · Febuxostat · Ruzinurad

Start the discussion